

Title (en)
DPP4 IMMUNOADHESIN COMPOSITIONS AND METHODS

Title (de)
DPP4-IMMUNOADHÄSINZUSAMMENSETZUNGEN UND VERFAHREN

Title (fr)
COMPOSITIONS D'IMMUNOADHÉSINE DPP4 ET PROCÉDÉS

Publication
EP 3227318 A4 20181212 (EN)

Application
EP 15866344 A 20151205

Priority
• US 201462124011 P 20141205
• US 2015064142 W 20151205

Abstract (en)
[origin: WO2016090345A1] Described herein fusion proteins comprising modified DPP4 binding sequence and the Fc of a human immunoglobulin, related compositions, and related methods for inhibiting MERS- CoV infection. In addition to the improved potency, the modified DPP4-Fc is also expected to have superior pharmacokinetics, as Fc will confer a long circulating half-life and the ability to be delivered to airway mucosal surfaces, the site of MERS-CoV infection. Unlike antibodies against MERS-CoV, a DPP4-Fc and the modified DPP4-Fc decoy of the invention will not subject the virus to selection for neutralization escape mutants, as any mutation that decreases binding to the decoy will decrease binding to the native receptor, resulting in an attenuated virus.

IPC 8 full level
A61K 31/14 (2006.01); **A61K 38/00** (2006.01); **A61K 39/12** (2006.01); **A61K 39/215** (2006.01); **A61K 39/42** (2006.01); **C07K 14/165** (2006.01); **C07K 14/47** (2006.01); **C07K 16/10** (2006.01); **C07K 19/00** (2006.01); **C12N 9/48** (2006.01); **C12N 15/63** (2006.01); **C12P 21/02** (2006.01)

CPC (source: EP)
A61K 39/12 (2013.01); **C12N 9/485** (2013.01); **C12Y 304/14005** (2013.01); **A61K 38/00** (2013.01); **C07K 2319/30** (2013.01); **C07K 2319/32** (2013.01); **C12N 2770/20011** (2013.01)

Citation (search report)
• [XY] WO 2014045254 A2 20140327 - UNIV ERASMUS MEDICAL CT [NL]
• [I] WO 2014134439 A1 20140904 - NEW YORK BLOOD CT INC [US], et al
• [A] V. STALIN RAJ ET AL: "Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC", NATURE, vol. 495, no. 7440, 13 March 2013 (2013-03-13), GB, pages 251 - 254, XP055302115, ISSN: 0028-0836, DOI: 10.1038/nature12005
• [Y] NIANSHUANG WANG ET AL: "Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4", CELL RESEARCH - XIBAO YANJIU, vol. 23, no. 8, 9 July 2013 (2013-07-09), GB, CN, pages 986 - 993, XP055302109, ISSN: 1001-0602, DOI: 10.1038/cr.2013.92
• [X] JIE CUI ET AL: "Adaptive evolution of bat dipeptidyl peptidase 4 (dpp4): implications for the origin and emergence of Middle East respiratory syndrome coronavirus", VIROLOGY JOURNAL, BIOMED CENTRAL, LONDON, GB, vol. 10, no. 1, 10 October 2013 (2013-10-10), pages 304, XP021164817, ISSN: 1743-422X, DOI: 10.1186/1743-422X-10-304
• [X] V. S. RAJ ET AL: "Adenosine Deaminase Acts as a Natural Antagonist for Dipeptidyl Peptidase 4-Mediated Entry of the Middle East Respiratory Syndrome Coronavirus", JOURNAL OF VIROLOGY., vol. 88, no. 3, 1 February 2014 (2014-02-01), US, pages 1834 - 1838, XP055483571, ISSN: 0022-538X, DOI: 10.1128/JVI.02935-13
• [Y] WENFEI SONG ET AL: "Identification of residues on human receptor DPP4 critical for MERS-CoV binding and entry", VIROLOGY, vol. 471-473, 1 December 2014 (2014-12-01), AMSTERDAM, NL, pages 49 - 53, XP055453503, ISSN: 0042-6822, DOI: 10.1016/j.virol.2014.10.006
• See references of WO 2016090345A1

Cited by
CN112043825A

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2016090345 A1 20160609; CA 2969891 A1 20160609; EP 3227318 A1 20171011; EP 3227318 A4 20181212

DOCDB simple family (application)
US 2015064142 W 20151205; CA 2969891 A 20151205; EP 15866344 A 20151205